How it works:
Nebivolol is a third-generation highly selective beta1-adrenergic blocker. It reduces heart rate and myocardial contractility, lowering cardiac oxygen demand. Additionally, it enhances nitric oxide release in vascular endothelium, resulting in vasodilation and further blood pressure reduction.
Clinical advantages include a favorable metabolic profile and minimal impact on glucose and lipid metabolism compared to non-selective beta-blockers.
Research background:
Clinical trials have demonstrated significant reductions in systolic and diastolic blood pressure.
Large-scale studies in chronic heart failure patients showed reduced hospitalization rates and improved prognosis, particularly in elderly populations.
Long-term studies confirm good tolerability and safety.
Recommended for:
Hypertension and chronic heart failure (as part of combination therapy). The medication lowers blood pressure, reduces cardiac workload, and improves hemodynamic stability.
Take orally once daily with water, with or without food. Dosage and duration of treatment are determined individually by a healthcare provider. Abrupt discontinuation is not recommended.
Contraindications:
Side effects:
